Abbott, AstraZeneca cholesterol combo
Executive Summary
Abbott and AstraZeneca have decided to pursue development of a combination of Abbott's next-generation fenofibrate ABT-335 with AstraZeneca's Crestor (rosuvastatin), the firms announce Aug. 31. The partnership to develop a multi-targeted fenofibrate/statin cholesterol combination was announced last year. However, the companies had not determined whether the product would use the investigational ABT-335 or Abbott's marketed drug, TriCor (fenofibrate). Abbott and AstraZeneca are targeting 2009 for submitting an NDA for the combination, which is expected to offer the LDL-C lowering benefits of Crestor and the HDL-C raising and triglyceride-lowering benefits of fibrates. Based on positive clinical trial results, Abbott also said it will file ABT-335 as monotherapy by year-end...
You may also be interested in...
AstraZeneca To Co-Promote Abbott’s TriLipix; NDA Is Filed For Crestor/TriLipix
AstraZeneca and Abbott announce co-promotion agreement for TriLipix ahead of an FDA decision on a jointly-developed investigational Crestor/TriLipix compound.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.